Brief: Sino Biopharmaceutical Announces Acceptance Of New Drug Application
18/07/2024 12:29
July 18 (Reuters) - Sino Biopharmaceutical Ltd
1177.HK :
* ACCEPTANCE OF NEW DRUG APPLICATION FOR CATEGORY 1
INNVOATIVE
DRUG CULMERCICLIB CAPSULE CULMERCICLIB (TQB3616)
* ACCEPTANCE BY NATIONAL MEDICAL PRODUCTS ADMINISTRATION
Further company coverage: 1177.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Sino Biopharmaceutical
See all newsHong Kong stocks end higher on pharma, tech gains
Hong Kong stocks climb, led by pharmaceutical, tech stocks
Brief: Sino Biopharmaceutical Says China's CDE Accepts NDA For TQH2722 Injection
Brief: Sino Biopharmaceutical China CDE Accepts New Drug Application For TQB2102 Injection
Sino Biopharmaceutical climbs on plan to raise stake in core unit